94 related articles for article (PubMed ID: 11977645)
1. [Capecitabine (xeloda) in the treatment of relapsed and metastatic breast cancer].
Liu X; Song S; Guan Z; Wu S; Duan Y; Yu J; Yang L
Zhonghua Zhong Liu Za Zhi; 2002 Jan; 24(1):71-3. PubMed ID: 11977645
[TBL] [Abstract][Full Text] [Related]
2. [Single-agent Xeloda in the treatment of recurrent and metastatic breast cancer].
Wang T; Jiang ZF; Song ST; Zhang SH; Shen G; Yu JX
Zhonghua Zhong Liu Za Zhi; 2004 Jun; 26(6):379-81. PubMed ID: 15312353
[TBL] [Abstract][Full Text] [Related]
3. Capecitabine: a review.
Walko CM; Lindley C
Clin Ther; 2005 Jan; 27(1):23-44. PubMed ID: 15763604
[TBL] [Abstract][Full Text] [Related]
4. Capecitabine (Xeloda) as monotherapy in advanced breast and colorectal cancer: effectiveness and side-effects.
Stathopoulos GP; Koutantos J; Lazaki H; Rigatos SK; Stathopoulos J; Deliconstantinos G
Anticancer Res; 2007; 27(3B):1653-6. PubMed ID: 17595791
[TBL] [Abstract][Full Text] [Related]
5. Reduced dose capecitabine is an effective and well-tolerated treatment in patients with metastatic breast cancer.
El-Helw L; Coleman RE
Breast; 2005 Oct; 14(5):368-74. PubMed ID: 16216738
[TBL] [Abstract][Full Text] [Related]
6. Phase I and II study of exisulind in combination with capecitabine in patients with metastatic breast cancer.
Pusztai L; Zhen JH; Arun B; Rivera E; Whitehead C; Thompson WJ; Nealy KM; Gibbs A; Symmans WF; Esteva FJ; Booser D; Murray JL; Valero V; Smith TL; Hortobagyi GN
J Clin Oncol; 2003 Sep; 21(18):3454-61. PubMed ID: 12972520
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of a novel capecitabine dosing schedule in combination with lapatinib for the treatment of patients with HER2-positive metastatic breast cancer.
Gajria D; Gonzalez J; Feigin K; Patil S; Chen C; Theodoulou M; Drullinsky P; D'Andrea G; Lake D; Norton L; Hudis CA; Traina TA
Breast Cancer Res Treat; 2012 Jan; 131(1):111-6. PubMed ID: 21898114
[TBL] [Abstract][Full Text] [Related]
8. Prospective study of vinorelbine and capecitabine combination therapy in Chinese patients with metastatic breast cancer pretreated with anthracyclines and taxanes.
Fan Y; Xu B; Yuan P; Wang J; Ma F; Li Q; Zhang P; Li Q; Cai R
Chemotherapy; 2010; 56(4):340-7. PubMed ID: 20720418
[TBL] [Abstract][Full Text] [Related]
9. Safety profile and activity of lower capecitabine dose in patients with metastatic breast cancer.
Rossi D; Alessandroni P; Catalano V; Giordani P; Fedeli SL; Fedeli A; Baldelli AM; Casadei V; Ceccolini M; Catalano G
Clin Breast Cancer; 2007 Dec; 7(11):857-60. PubMed ID: 18269775
[TBL] [Abstract][Full Text] [Related]
10. Study of low-dose capecitabine monotherapy for metastatic breast cancer.
Taguchi T; Nakayama T; Masuda N; Yoshidome K; Akagi K; Nishida Y; Yoshikawa Y; Ogino N; Abe C; Sakamoto J; Noguchi S;
Chemotherapy; 2010; 56(2):166-70. PubMed ID: 20407245
[TBL] [Abstract][Full Text] [Related]
11. Xeloda in the treatment of metastatic breast cancer.
Blum JL
Oncology; 1999 Jul; 57 Suppl 1():16-20. PubMed ID: 10436412
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial of capecitabine and weekly paclitaxel as first-line therapy for metastatic breast cancer.
Blum JL; Dees EC; Chacko A; Doane L; Ethirajan S; Hopkins J; McMahon R; Merten S; Negron A; Neubauer M; Ilegbodu D; Boehm KA; Asmar L; O'Shaughnessy JA
J Clin Oncol; 2006 Sep; 24(27):4384-90. PubMed ID: 16926223
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of capecitabine plus trastuzumab in human epidermal growth factor receptor 2 overexpressing metastatic breast cancer pretreated with anthracyclines or taxanes.
Schaller G; Fuchs I; Gonsch T; Weber J; Kleine-Tebbe A; Klare P; Hindenburg HJ; Lakner V; Hinke A; Bangemann N
J Clin Oncol; 2007 Aug; 25(22):3246-50. PubMed ID: 17577021
[TBL] [Abstract][Full Text] [Related]
14. Oral combination chemotherapy with capecitabine and cyclophosphamide in patients with metastatic breast cancer: a phase II study.
Tanaka M; Takamatsu Y; Anan K; Ohno S; Nishimura R; Yamamoto Y; Masuda N; Mitsuyama S; Tamura K;
Anticancer Drugs; 2010 Apr; 21(4):453-8. PubMed ID: 20075712
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of single agent capecitabine in pretreated metastatic breast cancer patients from the French compassionate use program.
Pierga JY; Fumoleau P; Brewer Y; Zelek L; Martin D; Turpin FL; Goudier MJ; Gil-Delgado M; Baticle JL; Namer M; Chollet P; Sutherland W; Barats JC;
Breast Cancer Res Treat; 2004 Nov; 88(2):117-29. PubMed ID: 15564795
[TBL] [Abstract][Full Text] [Related]
16. [First-line Xeloda (Capecitabine) treatment for advanced and recurrent colorectal cancer].
Guan ZZ; Liu DG; Yu BM; Wu WQ; Shi D; Zhao Y; Wei YQ; Zou LQ; Wu XD; Zhuang W; Feng FY; Zhang P; Yu SY; Xiong HH; Fu Q; Zheng S; Huang JJ; Wu G; Yang CY; Sun SR; Ruan QL
Zhonghua Zhong Liu Za Zhi; 2004 Feb; 26(2):119-21. PubMed ID: 15059335
[TBL] [Abstract][Full Text] [Related]
17. Capecitabine in breast cancer: current status.
Smorenburg CH; Bontenbal M; Verweij J
Clin Breast Cancer; 2001 Jan; 1(4):288-93; discussion 294. PubMed ID: 11899351
[TBL] [Abstract][Full Text] [Related]
18. Single-agent capecitabine maintenance therapy after response to capecitabine-based combination chemotherapy in patients with metastatic breast cancer.
Huang H; Jiang Z; Wang T; Zhang S; Bian L; Cao Y; Wu S; Song S
Anticancer Drugs; 2012 Aug; 23(7):718-23. PubMed ID: 22739713
[TBL] [Abstract][Full Text] [Related]
19. Capecitabine in the treatment of metastatic renal cell carcinoma failing immunotherapy.
Wenzel C; Locker GJ; Schmidinger M; Mader R; Kramer G; Marberger M; Rauchenwald M; Zielinski CC; Steger GG
Am J Kidney Dis; 2002 Jan; 39(1):48-54. PubMed ID: 11774101
[TBL] [Abstract][Full Text] [Related]
20. Single-agent capecitabine in patients with metastatic colorectal cancer refractory to 5-fluorouracil/leucovorin chemotherapy.
Lee JJ; Kim TM; Yu SJ; Kim DW; Joh YH; Oh DY; Kwon JH; Kim TY; Heo DS; Bang YJ; Kim NK
Jpn J Clin Oncol; 2004 Jul; 34(7):400-4. PubMed ID: 15342667
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
